Clinical Trials Logo

Clinical Trial Summary

Metoclopramide is a dopamine D2 receptor antagonist with antiemetic and gastrokinetic properties which has been approved for use in pregnant women. Women with polycystic ovary syndrome (PCOS) have been found to have lower dopaminergic tone and increased ovarian vascularity and vascular endothelial growth factor (VEGF) levels compared to controls. During ovarian stimulation, PCOS patients exhibit greater sensitivity to gonadotropins and increased follicular development. Administration of dopamine D2 antagonists may mimic the low dopaminergic tone noted in PCOS patients, increase VEGF levels, angiogenesis, and subsequently improve follicular growth during ovarian stimulation. This strategy could be used to improve IVF outcomes in poor responders. The investigators hypothesize that, compared to gonadotropin use alone, the use of metoclopramide in combination with gonadotropins in poor responders undergoing IVF will result in an increased number of mature oocytes obtained at oocyte retrieval and improved IVF outcomes.


Clinical Trial Description

Poor responders constitute a significant and challenging population of women to treat with in vitro fertilization (IVF). This population includes women who respond sub-optimally to conventional ovarian stimulation with poor follicular recruitment. The estimated incidence of poor ovarian response ranges from 9-26%. Patients with PCOS are on the opposite end of the spectrum from poor responders. They are often exquisitely sensitive to ovarian stimulation and are predisposed to over-respond with the development of ovarian hyperstimulation syndrome (OHSS). Understanding the underlying mechanisms that enhance their sensitivity may provide insight into the treatment of poor responders. VEGF is a glycoprotein produced by ovarian granulosa cells that enhances vascular permeability and angiogenesis, and has been implicated in the pathogenesis of OHSS. After ovulation is triggered by LH or hCG, follicular expression of VEGF increases, which is crucial for corpus luteum function and steroidogenesis. However, excessive VEGF production can lead to third-space shifts of fluids, ascites, and other life-threatening features of OHSS. Serum concentrations and granulosa cell expression of VEGF have been shown to be higher in women with PCOS than in controls. Interestingly, compared with controls, patients with PCOS have also been shown to have lower levels of the neurotransmitter dopamine and dopamine D2 receptor levels in the ovary. Administration of dopamine D2 agonists has been shown in animal and human studies to decrease ovarian VEGF production and reduce the risk of OHSS. In this study, the investigators propose a novel approach of administering a dopamine D2 antagonist to poor responders to mimic the low dopaminergic tone of PCOS patients, with the goal of increasing VEGF production and follicular development during ovarian stimulation. Metoclopramide is a dopamine D2 antagonist with antiemetic and prokinetic properties and an established safety profile in pregnancy. The investigators hypothesis is that metoclopramide use prior to, and in conjunction with, conventional gonadotropin stimulation can improve IVF outcomes in poor responders. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02262923
Study type Interventional
Source Mount Sinai Hospital, Canada
Contact
Status Withdrawn
Phase N/A
Start date March 2016
Completion date March 2018

See also
  Status Clinical Trial Phase
Completed NCT00696878 - Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) Phase 3
Recruiting NCT04122729 - N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
Not yet recruiting NCT02534857 - A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment N/A
Recruiting NCT01406600 - Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles N/A
Completed NCT01406028 - Does Emotional Support Decrease In Vitro Fertilization Stress? N/A
Withdrawn NCT00541892 - Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine Phase 2
Completed NCT00708383 - in Vitro Fertilization (IVF) Media Protein and Live Birth Rates N/A
Completed NCT03627533 - The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF N/A
Recruiting NCT04160611 - What Amount of Stress is Enough for a Successful Conception? Phase 3
Suspended NCT01600794 - To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization N/A
Completed NCT01507376 - Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity Phase 3
Terminated NCT00866008 - A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) Phase 4
Recruiting NCT04082650 - Vitamin D and Pregnancy Outcome in PCOS Patients N/A
Recruiting NCT03758833 - eSET or eDET Associated to PGT in IVF N/A
Not yet recruiting NCT04407871 - Acupuncture and Chinese Herbal Medicine to Improve Live Birth Rate of in Vitro Fertilization (IVFAct) N/A
Recruiting NCT03345030 - The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome N/A
Not yet recruiting NCT06367985 - CAPA-IVM Culture With Low Oxygen Tension N/A
Not yet recruiting NCT03090438 - IVF Outcomes After Varicocele Repair N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Completed NCT01343992 - Bed Rest or no Bed Rest? N/A